Dramavol

Quick links to important sections

Dramavol

Method of action: Antiemetic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dramavol

Property Description
Active ingredient Dimenhydrinate
Pharmacological class Antiemetic and First-Generation Antihistamine
Form Tablets, Syrup, or Injection
Common use Relief from Nausea, Vomiting, and Dizziness
Origin Synthetic derivative

What Type of Medicine is Dramavol? (Classification and Origin)

Dramavol is the trade name for a medication containing the active substance Dimenhydrinate, which is classified as an antiemetic (anti-nauseant) and a first-generation antihistamine. This substance is a synthetic derivative belonging to the ethanolamine class. Its dual activity is clinically recognized for its role in the management of symptoms arising from motion and balance disturbances, particularly in settings such as travel.

The medication's fundamental purpose is to provide relief from acute symptoms of nausea, vomiting, and dizziness. Its primary indication is for the prevention and treatment of symptoms related to motion sickness. This recognized use means the medication effectively helps stabilize the body's reaction to movement and motion. Due to its classification, Dimenhydrinate, sold widely under various trade names, is one of the most established treatments for this purpose.


Dimenhydrinate Composition: A Combination Theoclate Salt

The core active ingredient, Dimenhydrinate, is chemically structured as a combination product known as a theoclate salt, derived from two distinct molecular entities. This salt is composed of Diphenhydramine, which supplies the antihistaminic activity, and 8-chlorotheophylline, a mild central nervous system stimulant.

This unique dual-component structure is a key differentiator, as the stimulant component is designed to modulate the characteristic sedative effects of Diphenhydramine alone, aiming for a more balanced therapeutic effect. Dimenhydrinate is available for oral intake in common dosage forms such as tablets or syrup, and is also formulated for parenteral (Intramuscular or Intravenous) administration when the oral route is not feasible.


Mechanism and Purpose (High-Level Summary)

The fundamental purpose of Dimenhydrinate is to calm the over-stimulated balance centers in the brain, thereby preventing or relieving symptoms of motion sickness and other forms of vestibular disturbances. It achieves this through a dual action involving H1-receptor antagonism and anticholinergic properties, which block the transmission of nerve signals from the inner ear. By depressing the hyper-activity within the labyrinthine function (the inner ear's sensory system), the medication effectively reduces the intensity of signals related to imbalance that would otherwise trigger the vomiting center.

Regulatory References

  1. Dimenhydrinate: MedlinePlus Drug Information
  2. Dimenhydrinate - LiverTox - NCBI Bookshelf - NIH

What side effects are possible with Dramavol?

Possible Side Effects and Safety Information

The safety profile of Dramavol (dimenhydrinate) is primarily determined by effects linked to its antihistaminic and anticholinergic properties, as documented in official government regulatory labels.

Adverse reactions are formally categorized by incidence rate and the body system affected.


Frequency-Classified Adverse Reactions

Adverse effects are grouped according to the frequency standards used by regulatory authorities:

  • Very Common: The most frequently documented reactions are drowsiness and sedation, often noted to be more pronounced at the initiation of treatment.
  • Common: Reactions occurring regularly include headache, dizziness, dry mouth, tachycardia (fast heart rate), and hypotension (low blood pressure).
  • Uncommon to Rare: Less frequent effects include blurred vision, constipation, urinary retention, and allergic skin reactions.

System-Organ Classes and Serious Reactions

Adverse reactions are formally classified into system-organ classes, with high incidence in Nervous System Disorders and Gastrointestinal Disorders. The label documents potential Serious Adverse Reactions, which, while rare, may include convulsions/seizures and blood dyscrasias. Use of the medicine may require particular caution when administered concomitantly with other substances that cause central nervous system (CNS) depression.


Population-Specific Safety Considerations

The official prescribing information includes specific safety notes for certain patient populations. Older adults may have an increased risk of adverse effects such as confusion, dizziness, and urinary retention due to heightened sensitivity. In the pediatric population, there is potential for a paradoxical reaction involving excitation or restlessness rather than the expected sedation. Furthermore, the medicine is subject to safety restrictions, including documented caution in patients with conditions such as angle-closure glaucoma and prostatic hypertrophy.

Overdose and Emergency Response

The official regulatory profile for Dramavol (Dimenhydrinate) overdose is defined by the severe effects of its first-generation antihistamine component, which can lead to a systemic anticholinergic toxidrome.

Property Official Regulatory Statement
Documented Overdose Presentations Overdose manifests as anticholinergic signs, including agitation, confusion, hallucinations, tremor, enlarged pupils, dry mouth, and tachycardia ( rapid heartbeat).
Physiological Systems Affected Severe toxicity targets the Central Nervous System ( CNS) and Cardiovascular System, resulting in seizures, delirium, respiratory depression, and serious heart rhythm disturbances.
Population-Specific Overdose Notes Children have a distinct toxic dose threshold (ge 7.5 mg/kg) that requires emergency department referral. Pediatric patients are noted to be more prone to agitation and seizures.
When Immediate Medical Help is Required Seek immediate medical attention or call the Poison Help line ( 1-800-222-1222) for any suspected overdose or development of symptoms beyond mild drowsiness.

Regulatory Basis and Management: The official guidance classifies this as a potential for life-threatening complications and requires symptomatic and supportive treatment. Monitoring protocols mandate the measurement of vital signs and continuous ECG monitoring. Procedural steps include the use of activated charcoal, but official documents mandate Do not induce emesis. These steps are required to manage the documented toxicity and stabilize the patient.

Therapeutic Uses of Dramavol

Quick Facts

  • Relief Domain: Motion Sickness
  • Targeted Symptoms: Nausea, vomiting, and dizziness
  • Primary Use: Prevention and management of symptoms related to motion

What Dramavol Helps With: Primary Indications

Dramavol (dimenhydrinate) is indicated for the prevention and treatment of symptoms associated with motion sickness. This medicinal product is a suitable option for managing the distress that may arise from travel-related motion, such as during car rides, plane flights, or boat trips.

The primary therapeutic benefit of Dramavol is to offer relief from specific symptoms linked to motion, including feelings of sickness, the urge to vomit, and dizziness. Timely use is appropriate to help mitigate the onset of these uncomfortable physical responses.

Eligibility and Restrictions for Use

Official regulatory documents establish strict eligibility rules for Dramavol (dimenhydrinate) concerning patient populations. Use is generally permitted for adults, adolescents, and children aged two years and older for over-the-counter oral formulations.

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the drug or its components, including diphenhydramine. Use is strictly prohibited in neonates and premature infants. It is also contraindicated for use concurrently with other preparations containing diphenhydramine. In some regulatory regions, narrow-angle glaucoma and concurrent use of Monoamine Oxidase Inhibitors (MAOIs) are listed as absolute prohibitions.

Use requires caution and is restricted in several populations. Older adults (65 years and older) are classified as a use-with-caution group due to anticholinergic effects. Patients with conditions such as glaucoma, urinary obstruction, severe respiratory or heart conditions, or seizure disorders must use the medicine conditionally. Additionally, its use status is restricted for individuals with hepatic (liver) or renal (kidney) impairment. For pregnancy, it holds an FDA Category B status, and due to its presence in human milk, a decision to discontinue nursing or the drug is required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dramavol (Dimenhydrinate) has several officially documented interaction patterns that regulate its use with other medicines and products. The most restrictive interactions are the Contraindicated Combinations. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited and requires a minimum separation of 14 days. Additionally, the injectable formulation is contraindicated in neonates and premature infants due to the presence of Benzyl Alcohol.

Pharmacodynamic and Exposure Effects

The primary Pharmacodynamic Interactions involve additive effects, notably with Alcohol and other Central Nervous System (CNS) Depressants (such as opioids, sedatives, and tranquilizers), which significantly increases the risk of sedation. An additive effect also occurs with other Anticholinergic Agents. Furthermore, Dimenhydrinate can mask the warning symptoms of ototoxicity caused by certain medications, including aminoglycoside antibiotics. A key Pharmacokinetic Interaction exists because its component, Diphenhydramine, inhibits the CYP2D6 enzyme, which can potentially decrease the clearance and increase the plasma concentration of co-administered CYP2D6 substrates. This potentiation leads to formal constraints, such as the documented regulatory suggestion that the dose of certain Narcotic Analgesics and Barbiturates should be reduced when co-administered.

Mechanism of Action

How Dramavol Works

Dramavol (Dimenhydrinate) exerts its physiological influence by engaging two distinct, yet complementary, mechanistic domains within the central nervous system (CNS).


Central Signal Blockade and Vestibular Depression

The primary mechanism involves the competitive antagonism of both central Histamine mathbfH1 receptors and Muscarinic Cholinergic receptors. This action is predominantly focused on the vestibular nuclei and the Chemoreceptor Trigger Zone (CTZ) in the brain, which are critical areas for processing balance and emetic signals. By blocking the binding of their respective neurotransmitters, the drug initiates a mechanistic cascade that leads to the depression of labyrinthine function and the attenuation of sensory signal overactivity, which results in a modulated physiological response to motion.


️ Combination Mechanism and Physiological Balancing

Dimenhydrinate is chemically structured as a salt containing two functional molecules, leading to a coordinated mechanistic effect. While the primary component provides blockade of emetic signal pathways, the secondary component, mathbf8-chlorotheophylline, acts as an Adenosine receptor antagonist. This mild central stimulatory mechanism modulates and partially offsets the CNS depressant consequence that is intrinsically linked to the mathbfH1 receptor blocking component, resulting in an altered state of central arousal.

Dosage and Administration Information

Official Administration Guidelines for Dramavol (Dimenhydrinate)

The administration of Dramavol is defined by the route, dosage, frequency, and preparation requirements. Dimenhydrinate is available for Oral intake (tablets, syrup, or liquid), as well as Intramuscular (IM), Intravenous (IV) injection, and Rectal suppository administration. Parenteral routes (IM/IV) are typically reserved for use when oral administration is not practical.

Standard Dosing and Frequency

Population Dose Range (per dose) Maximum Dose (24 hours) Frequency
Adults (and 12+ yrs) 50 mg to 100 mg Not to exceed 400 mg Every 4 to 6 hours, as needed
Children (6–11 yrs) 25 mg to 50 mg Not to exceed 150 mg Every 6 to 8 hours, as needed
Children (2–5 yrs) 12.5 mg to 25 mg Not to exceed 75 mg Every 6 to 8 hours, as needed

The first dose of the medication is to be taken 30 minutes to 1 hour prior to the anticipated start of motion exposure. Oral forms may be taken with or without food, as directed by the label.

Specific Administration Requirements

Intravenous administration requires adherence to precise procedural conditions. The injectable solution must be diluted with at least 10 mL of 0.9% Sodium Chloride Injection. The resulting mixture is then administered slowly over a period of at least two minutes. Liquid oral formulations must be measured accurately using a calibrated device to ensure proper dosage. The overall usage pattern is defined by these numerical limits and timing rules.

Recent Clinical Evidence

Dramavol: Recent Clinical Evidence


Evidence for Motion Sickness and Dizziness

Research has extensively examined Dramavol (dimenhydrinate) in studies exploring symptom patterns related to motion sickness and travel-induced discomfort. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. Research has explored outcomes such as the number of participants who did not experience motion sickness symptoms and changes in reported nausea symptom scores. Studies reported a lower proportion of participants developing symptoms compared to placebo. The evidence contributing to this understanding is broadly classified as High for its application in preventing symptoms in natural conditions.

Evidence for Acute Vertigo and Post-Operative Nausea

Dramavol was studied for its use in research exploring acute vertigo and in studies focusing on the prevention of post-operative nausea and vomiting (PONV). For vertigo, research often utilized RCTs evaluating the medicine as a fixed-dose combination, with measurements describing how symptoms evolved over periods of one to four weeks. For PONV, studies monitored outcomes such as the incidence of emetic symptoms and the need for rescue antiemetic medication in surgical patients. The evidence quality for both these applications is generally assessed as Moderate.

Evidence Gaps and Limitations

The research highlights several areas where information is limited. The evidence is less extensive for addressing motion sickness symptoms once they have already started compared to prevention. Furthermore, data for certain groups remains insufficient, particularly the overall evidence on the use and administration patterns for very young children. Research on precise dosage or administration intervals for use in preventing PONV is not fully established. Because most studies are acute, limited information for long-term outcomes is available, and some foundational RCTs had small sample sizes, which can influence the certainty of the findings.

Key Studies & References

  1. Efficacy and safety of dimenhydrinate in the treatment of vertigo: A systematic review of randomized clinical trials

Frequently Asked Questions (FAQ)

Common questions about Dramavol (FAQ)

Q: What is the typical time it takes for a person to start noticing effects from Dramavol?

A: Official instructions align the timing of the drug with the anticipation of motion. Regulatory guidelines advise taking the first dose 30 minutes to 1 hour before motion exposure is expected to begin. Official guidance indicates that for the purpose of prophylaxis (prevention), the first dose is taken within this period.

Q: Can Dramavol be used for long periods of time?

A: Dimenhydrinate (Dramavol) is primarily studied and intended for short-term use, such as treating temporary motion sickness symptoms. Official warnings indicate that chronic, heavy use carries a risk of developing tolerance, and as a consequence of tolerance, higher exposure may be necessary to achieve a similar effect over time.

Q: If I miss a dose of Dramavol, what do official instructions suggest?

A: Regulatory-aligned patient information generally advises taking the missed dose as soon as possible. However, if the time is almost right for the next scheduled dose, the guidance is to bypass the missed dose entirely. This approach is recommended to prevent accidental double dosing.

Q: Is the medication designed to be swallowed whole or can it be crushed?

A: Official instructions depend on the form of the medication. Non-chewable tablets are not recommended to be crushed or broken, as this can affect the intended delivery. If a solid form needs alteration, specific chewable or liquid formulations exist for accurate preparation.

Q: How long does the effect of a dose of Dramavol typically last?

A: The expected duration of the drug’s effect is reflected in the suggested dosing frequency. Official labeling indicates that adults should take a dose approximately every 4 to 6 hours as needed, which is the time frame over which the therapeutic effect is typically sustained.

Q: If I have kidney problems, does that change how I can use Dramavol?

A: Regulatory documents state that patients with renal (kidney) disease should use Dramavol cautiously. Because of the potential for the drug to accumulate in the body when kidney function is impaired, it is described that lower initial dosages may be appropriate for this population.

Q: Is Dramavol associated with any specific warnings for people with liver disease?

A: Official warnings advise that Dramavol should be administered with caution in patients who have liver (hepatic) disease due to potential drug accumulation. Initial administration patterns often involve careful monitoring for individuals in this population.

Q: Why do official documents mention the importance of lab monitoring when taking Dramavol?

A: Regulatory documents note that serious, though rare, adverse reactions may include blood dyscrasias, which are conditions affecting the blood cells. Lab monitoring is a standard procedure associated with medications that carry this potential risk, as a precautionary measure related to potential serious effects.

Q: What are the official restrictions on using Dramavol while breastfeeding?

A: Official information indicates that small amounts of Dimenhydrinate are excreted into breast milk. Due to the potential for adverse effects on a nursing infant, the regulatory guidance is that a decision must be made to either stop breastfeeding or discontinue the drug.

Q: Are there any special considerations for people over 65 taking Dramavol?

A: Yes, regulatory information advises that older adults may experience increased sensitivity to side effects, particularly drowsiness, confusion, dizziness, and difficulty urinating. Because of this heightened risk profile, official documents describe that a lower initial dose is often considered for this population.

Q: Has Dramavol been studied in children?

A: Yes, Dramavol is officially labeled with specific dosing schedules for children as young as two years old. However, official warnings note the potential for a paradoxical reaction in the pediatric population, which may involve hyperactivity or restlessness instead of sedation.

Q: Can Dramavol make certain medical conditions worse?

A: Regulatory precautions note that Dramavol should be used with caution in patients who have specific pre-existing conditions. These include narrow-angle glaucoma, prostatic hypertrophy, and severe heart conditions, as the drug's properties may potentially aggravate these issues.

Q: What is the reason why people with a history of heart issues are cautioned about Dramavol?

A: Dimenhydrinate is associated with cardiovascular side effects, including the potential for tachycardia (a rapid heart rate) and changes in blood pressure. Official documents advise caution for individuals with pre-existing cardiovascular disease or hypertension due to these possible effects.

Q: What does the patient information leaflet say about alcohol use while on Dramavol?

A: Official regulatory warnings emphasize that combining Dramavol with alcohol or other central nervous system depressants can significantly increase the risk of side effects. This combination results in an additive sedative effect, leading to severe drowsiness.

Q: Is Dramavol available over the counter?

A: Yes, Dimenhydrinate (Dramavol) is commonly available for purchase as an over-the-counter (OTC) medication. Its primary regulatory indication is for the prevention and treatment of symptoms related to motion sickness.

Q: Are there any known foods or drinks that should be limited while taking Dramavol?

A: The most significant restriction officially noted relates to the use of alcohol due to its additive sedative effect. Official documents do not typically specify major restrictions on specific foods while taking the medication.

Q: What is the purpose of the black box warning on Dramavol's label?

A: Dimenhydrinate itself is not subject to a Black Box Warning, which is the FDA's most stringent regulatory requirement. However, official warnings highlight the drug’s ability to mask the signs of ototoxicity (ear damage) caused by other medications.

Q: Is Dramavol considered a controlled substance?

A: No, Dimenhydrinate is officially classified by regulatory bodies as a non-controlled medication. It is typically regulated as an over-the-counter drug for its primary indications.

Q: Does taking Dramavol affect driving or operating machinery?

A: Yes, official warnings caution patients against engaging in activities that require full mental alertness, such as driving or operating heavy machinery. This restriction is due to the potential for significant drowsiness and reduced coordination caused by the medication.

Q: What happens if Dramavol is stopped suddenly?

A: Official information indicates that Dimenhydrinate can lead to psychological dependency when used chronically and heavily. In such cases, abrupt discontinuation may cause withdrawal symptoms, which have been reported to include lethargy, confusion, agitation, and aggression.

Q: Is there a generic version of Dramavol?

A: Yes, the active ingredient in Dramavol, known as Dimenhydrinate, is widely available as a generic medication. The generic formulation is often used as a lower-cost option compared to the branded product.

Q: Can Dramavol be taken with pain relievers like ibuprofen or acetaminophen?

A: Regulatory sources generally do not report severe or major interactions between Dimenhydrinate and common non-opioid pain relievers like ibuprofen or acetaminophen. Some over-the-counter products even combine similar antihistamines with these pain relievers.

Q: Does Dramavol carry a risk of dependence or withdrawal?

A: Official regulatory warnings note that tolerance to the effects of Dimenhydrinate can develop with chronic use. Furthermore, psychological dependency may occur in some individuals using the drug heavily and over prolonged periods.

Q: Is it possible to develop a tolerance to Dramavol over time?

A: Yes, official regulatory documents state that tolerance can develop, especially with sustained, heavy use of the medication. This means that a person may find that higher dosages are eventually required to achieve the same initial therapeutic effect.

Q: Does the efficacy of Dramavol change when taken with antacids?

A: Regulatory-aligned drug interaction checkers do not indicate a severe or major interaction that significantly alters the effectiveness of Dimenhydrinate when taken with antacids. This should be considered alongside specific administration guidance provided for the drug.

Q: How does the body process Dramavol?

A: According to official pharmacokinetic information, Dramavol is distributed widely throughout the body, including entering the central nervous system. The drug is primarily broken down and metabolized by the liver, with a portion of the drug excreted from the body through the urine.

Q: What does the FDA label say about Dramavol and mood changes?

A: Official documents list mental and mood changes as potential adverse effects associated with the drug. These reported effects can include feelings of nervousness, confusion, excitement, and restlessness.

How should Dramavol be stored and disposed of?

How to Store and Dispose of Dramavol

Official regulatory labeling dictates specific conditions necessary to preserve the quality and safety of dimenhydrinate (Dramavol).


Required Storage Conditions

Dramavol must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product requires protection from moisture and must be kept in the original container with the lid tightly closed.

Product Integrity and Safety

For stability, the regulatory documents advise against use if the packaging or blister is visibly torn or broken. Most importantly, for household safety, the medicine must be stored out of the reach of children.


Disposal

Unused or expired dimenhydrinate should be handled according to established local guidelines for medication disposal, such as drug take-back programs, to ensure environmental safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dramavol found in:

A-Z Index: